The 503A Bulks List for Peptides: Status, Categories, and How to Verify

Educational content only. Not medical advice. FeelGood does not claim that any peptide treats, cures, prevents, or mitigates any disease or condition. Consult a qualified healthcare provider before making any decisions about peptide therapy.

The question behind most searches that pair a peptide name with "503A" is a simple one: can a compounding pharmacy legally prepare this. For every research peptide in wide circulation, the answer as of mid-2026 is no, and the reasons are widely misreported. This page is a standing reference. It sets out where each peptide sits on the FDA's 503A framework today, what the categories mean, why the April 2026 news did not change what is compoundable, and how to verify the status of any peptide from primary sources. For what a 503A pharmacy is, see the explainer on the 503A compounding pharmacy. For the July 2026 advisory meeting in detail, see the PCAC meeting explainer.

This sits within the wider question of peptide legality. For how United States law treats peptides overall, see the overview on whether peptides are legal.

The current 503A status of peptides, at a glance

No research or wellness peptide is on the finalized 503A bulk drug substances list. That list is codified at 21 CFR 216.23, and it contains six substances, none of them peptides: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide, the last five limited to topical use. [1] Every peptide discussed below sits in the interim, pre-finalization process, not on that codified list.

The peptides that draw the most attention all moved through the FDA's interim Category 2 list. In April 2026 the agency removed twelve of them from Category 2, and seven of those are scheduled before an advisory committee on July 23 and 24, 2026. [2] [3]

The seven peptides scheduled for the July 2026 Pharmacy Compounding Advisory Committee meeting, each removed from Category 2 in April 2026:

• BPC-157, also written Body Protection Compound-157. Reviewed July 23. Not on Category 1, and not eligible for 503A compounding.
• KPV, a lysine-proline-valine fragment. Reviewed July 23. Same status.
• TB-500, a thymosin beta-4 fragment. Reviewed July 23. Same status.
• MOTs-C. Reviewed July 23. Same status.
• Emideltide, also called delta sleep-inducing peptide, or DSIP. Reviewed July 24. Same status.
• Semax. Reviewed July 24. Same status.
• Epitalon, a Khavinson bioregulator also written epithalon. Reviewed July 24. Same status.

Five more peptides were removed from Category 2 in April 2026 but are not on the July agenda. Reporting from regulatory counsel indicates a separate evaluation for these in early 2027:

• GHK-Cu, copper tripeptide-1, in both its injectable and non-injectable forms.
• Melanotan II.
• Cathelicidin LL-37.
• Dihexa.
• PEG-MGF, pegylated mechano growth factor.

One point of caution on GHK-Cu specifically. Its non-injectable form previously carried Category 1 enforcement discretion, and the April 2026 action removed it. Some secondary sources report a later restoration of non-injectable GHK-Cu to Category 1 in May 2026, but that claim could not be confirmed against an FDA primary source and conflicts with the documented April removal. This page treats GHK-Cu's current status as unsettled rather than restored.

None of these placements is the finalized list. The category is the FDA's interim evaluation status, and the rest of this page explains why that distinction is the whole story.

The short answer: no wellness peptide is finalized on the 503A list

A 503A pharmacy may compound with a bulk drug substance only when that substance is the subject of an applicable monograph, is a component of an approved drug, or appears on the FDA's 503A bulks list. The codified bulks list at 21 CFR 216.23 holds the six non-peptide substances named above. [1] Because no research peptide appears there, the honest answer to "is this peptide on the 503A bulks list" is no for every wellness peptide on the market. The activity around peptides in 2026 concerns the interim evaluation lists that precede codification, not the codified list itself.

How the list works: Category 1, Category 2, and why removal is not legalization

While the FDA evaluates nominated substances, it has sorted them into interim categories. Category 1 covers substances for which the agency exercises enforcement discretion, meaning it does not intend to act against a compounder who uses them while review continues. Category 2 covers substances the agency has identified as raising significant safety risks; they receive no enforcement discretion, and the agency would consider action against their use. [4] Both are interim guidance categories that exist only until the FDA issues a final rule placing a substance on, or leaving it off, the 216.23 list.

This is where the April 2026 news is most often misread. Removing a peptide from Category 2 did not move it to Category 1, and it did not make it eligible for 503A compounding. The mechanism was the withdrawal of the nominations, which deletes a substance from the evaluation list rather than promoting it. As the regulatory counsel who tracked the action put it, the removed peptides "were never on Category 1," and removal "does not render these bulk drug substances eligible for compounding under section 503A." [2] [5] A peptide removed from Category 2 is therefore neither restricted as a named safety risk nor cleared for compounding. It has simply left the interim evaluation, pending whatever the advisory committee and any later rulemaking decide.

The seven peptides under the July 2026 PCAC review

The Pharmacy Compounding Advisory Committee is scheduled to meet on July 23 and 24, 2026, to consider whether the seven peptides listed above should be added to the 503A bulks list. The meeting was established by a Federal Register notice published April 16, 2026, which opened public docket FDA-2025-N-6895. [3] The committee votes a recommendation; it does not decide. A favorable recommendation would not by itself add any peptide to the list, because addition proceeds through notice-and-comment rulemaking, a process measured in years rather than weeks. The meeting and its agenda are covered in full in the PCAC meeting explainer.

Why the list keeps changing: 2023 to 2026

Three events explain the confusion a reader encounters when searching this topic.

In September 2023, the FDA moved more than a dozen nominated peptides into Category 2, citing insufficient data and safety concerns. Sources give different counts for that cohort, commonly seventeen, so the conservative description is "more than a dozen." [4]

On January 7, 2025, the agency retired its 2017 interim policy on categorizing nominated bulk substances and stopped publishing categorizations for substances nominated on or after that date. [6] Existing Category 1 placements kept their enforcement discretion; Category 2 and uncategorized substances received none.

In April 2026, the FDA removed twelve peptides from Category 2 by accepting the withdrawal of their nominations, and it scheduled the seven listed above for the July advisory meeting. [2] [3] This is the action most often described, incorrectly, as the FDA loosening restrictions on peptides.

How to check the current 503A status of a specific peptide

The status of any single peptide can be confirmed from primary sources in four steps.

1. Check the codified list at 21 CFR 216.23 through the eCFR. A substance that appears there is finalized for 503A compounding. As of mid-2026, no wellness peptide does. [1]
2. Check the FDA's "Bulk Drug Substances Used in Compounding under Section 503A" page and its nominations document for any interim Category 1 enforcement-discretion placement. [4]
3. Check the advisory-committee meeting materials and the Federal Register docket for anything currently under review, such as docket FDA-2025-N-6895 for the July 2026 meeting. [3]
4. Confirm with the compounding pharmacy or the relevant state board of pharmacy. A 503A pharmacy will compound only with a substance it can legally source, which means a monograph substance, a component of an approved drug, or a listed bulk substance.

How a substance gets added to the 503A bulks list

The path from a peptide name to the codified list is deliberate and slow. A substance is first nominated for the list. The FDA evaluates the nomination and, under the framework that operated through early 2025, sorted it into an interim category. A nominated substance may be referred to the Pharmacy Compounding Advisory Committee, which reviews the evidence and votes a non-binding recommendation. The agency then decides whether to proceed, and any addition is made through notice-and-comment rulemaking and codified at 21 CFR 216.23. Because each stage can take months or years, the list is a slow-moving record rather than a live status feed, which is why a peptide can sit in evaluation limbo for years without ever being either listed or formally rejected.

Frequently asked questions

Is BPC-157 on the 503A bulks list? No. BPC-157 does not appear on the codified 503A bulks list at 21 CFR 216.23. It was removed from the interim Category 2 list in April 2026 as a step toward the July 2026 advisory review, and it was never on Category 1. It is not eligible for 503A compounding. [1] [2]

What is the difference between Category 1 and Category 2 on the 503A framework? Category 1 covers nominated substances for which the FDA exercises enforcement discretion during review. Category 2 covers nominated substances the FDA has flagged as raising significant safety risks, which receive no enforcement discretion. Both are interim evaluation categories, separate from the finalized 216.23 list. [4]

Which peptides can a 503A pharmacy compound right now? None of the research or wellness peptides in wide circulation are on the finalized 503A bulks list, so none qualifies on that basis. The codified list at 21 CFR 216.23 contains six non-peptide substances. [1]

Does removal from Category 2 mean a peptide is now legal to compound? No. Removal from Category 2 deletes a substance from the interim evaluation; it does not place the substance on Category 1 and does not make it eligible for 503A compounding. The peptides removed in April 2026 were never on Category 1. [2] [5]

Where is the official FDA 503A bulks list? The codified list is 21 CFR 216.23, available through the eCFR. The interim category placements are published in the FDA's bulk-substances compounding materials, and substances under review appear in Federal Register dockets such as FDA-2025-N-6895. [1] [3] [4]

How does a peptide get added to the 503A bulks list? Through nomination, FDA evaluation, possible advisory-committee review, and notice-and-comment rulemaking, after which the substance is codified at 21 CFR 216.23. The process typically takes years. [3] [4]

Sources

1. Electronic Code of Federal Regulations. 21 CFR 216.23, Drug products or categories of drug products that may not be compounded under the exemptions, and bulk drug substances that can be used to compound drug products. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23
2. Hyman, Phelps & McNamara, FDA Law Blog. "FDA's Peptide Rally: What Compounders and Industry Need to Know," April 2026. https://www.thefdalawblog.com/2026/04/fdas-peptide-rally-what-compounders-and-industry-need-to-know-post-1-of-2/
3. Food and Drug Administration. "Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments." Federal Register, April 16, 2026, FR Doc. 2026-07361. Docket FDA-2025-N-6895. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
4. Food and Drug Administration. "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act." https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
5. Frier Levitt. "FDA Peptides Do-Not-Compound List Update 2026." https://www.frierlevitt.com/articles/fda-peptides-do-not-compound-list-update-2026/
6. Food and Drug Administration. "Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A," and the January 7, 2025 Federal Register availability notice. https://www.federalregister.gov/documents/2025/01/07/2024-31546/